Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to ...
TG Therapeutics, Inc. (NASDAQ: TGTX), announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the Company’s anti-CD20 monoclonal antibody, in ...
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLO ...
A woman in her 50s with genetically confirmed Huntington’s disease presented with right-sided arm sensory symptoms that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results